Aurigene and Vipergen Collaborate for Advanced Drug Discovery Services

• Aurigene Pharmaceutical Services and Vipergen ApS have formed a partnership to co-market and offer DNA encoded library (DEL) screening technologies.

• The partnership aims to co-develop new DELs, enhancing Aurigene’s Integrated Drug Discovery (IDD) service offering.

Aurigene Pharmaceutical Services, a global contract research, development, and manufacturing services organization (CRDMO), has announced a strategic partnership with Vipergen ApS, a niche small-molecule drug discovery service provider. The partnership aims to co-market and offer DNA encoded library (DEL) screening technologies to global customers, either as a standalone service or as an integrated drug discovery service.

The collaboration will also focus on the co-development of new DELs, with an emphasis on novel chemical diversity and drug-likeness, to further strengthen their service offering. This move is expected to enhance Aurigene’s existing small molecule discovery capabilities, from compound resynthesis to candidate nomination.

With the addition of hit screening capabilities, Aurigene aims to enhance its Integrated Drug Discovery (IDD) service offering to its global customers. The partnership with Vipergen is a strategic addition to Aurigene’s capabilities, particularly in the area of contract manufacturing and drug discovery.

Akhil Ravi, CEO of Aurigene, expressed his enthusiasm about the partnership, stating, “The partnership with Vipergen emphasizes our commitment to accelerating innovation and customer-centric approach. The recent launch of Aurigene.AI for small molecules and DEL partnership with Vipergen aim to reduce the hit finding timelines. Vipergen’s proven track record, with more than 90 partnerships with big pharma and biotech companies, and their streamlined hit finding platform, makes Vipergen the ideal strategic partner for us.”

Nils Jakob Vest Hansen, PhD, CEO of Vipergen, also shared his excitement about the partnership, “We are excited to partner with Aurigene, a global CRDMO focused on customer service. Aurigene’s drug discovery capabilities and global reach makes it a perfect match for Vipergen. I am looking forward to a successful partnership, and to offering our proprietary technologies to global customers.”